GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01239251|
Recruitment Status : Terminated
First Posted : November 11, 2010
Last Update Posted : March 6, 2015
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: GlowCap device|
|Study Type :||Observational|
|Actual Enrollment :||8 participants|
|Official Title:||Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||November 2011|
breast cancer patients taking endocrine therapy
Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
Other: GlowCap device
Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
- Assess the usability of the GlowCap system by patients [ Time Frame: 2 years ]>60 years of age with early stage breast cancer.
- Measure the acceptance and satisfaction of the GlowCap reminder system [ Time Frame: 2 years ]with respect to medication adherence in patients >60 years with early stage breast cancer taking adjuvant endocrine therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239251
|United States, New York|
|Memorial Sloan Kettering Cancer Center 1275 York Avenue|
|New York, New York, United States, 10065|
|Principal Investigator:||Tiffany Traina, MD||Memorial Sloan Kettering Cancer Center|